# Bial - Portela C S.A. clinical trials: 136 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 136 trials with Bial - Portela C S.A. as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Bial - Portela C S.A.: 136 rows for $6.80, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/bial-portela-c-s-a

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 136
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 136, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 11, 2026 | NCT07403799 | REal-life ON PARKinson's - ITaly (REONPARK-IT) | Bial - Portela C S.A. | Observational | Active not recruiting | Parkinson Disease | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07403799) |
| September 15, 2025 | NCT07173738 | Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and Furosemide | Bial - Portela C S.A. | Phase 1 | Completed | Pulmonary Arterial Hypertension | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07173738) |
| August 28, 2025 | NCT07145190 | SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment | Bial - Portela C S.A. | Observational | Recruiting | Parkinson Disease | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07145190) |
| September 19, 2024 | NCT06597084 | Anti-epileptogenic Effects of Eslicarbazepine Acetate | Bial - Portela C S.A. | Phase 2 | Completed | Post Stroke Epilepsy | 129 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06597084) |
| August 24, 2023 | NCT06009185 | Safety and Efficacy of BIA 5-1058 in PAH | Bial - Portela C S.A. | Phase 2 | Completed | Pulmonary Arterial Hypertension | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06009185) |
| August 6, 2021 | NCT04994860 | Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil | Bial - Portela C S.A. | Phase 1 | Completed | Pulmonary Arterial Hypertension | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04994860) |
| August 6, 2021 | NCT04994119 | Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics | Bial - Portela C S.A. | Phase 1 | Completed | Pulmonary Arterial Hypertension | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04994119) |
| August 5, 2021 | NCT04991207 | Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Bosentan | Bial - Portela C S.A. | Phase 1 | Completed | Pulmonary Arterial Hypertension | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04991207) |
| August 5, 2021 | NCT04991194 | Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058 | Bial - Portela C S.A. | Phase 1 | Terminated | Pulmonary Arterial Hypertension | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04991194) |
| August 5, 2021 | NCT04991181 | Absorption, Distribution, Metabolism and Excretion of BIA 5-1058 | Bial - Portela C S.A. | Phase 1 | Completed | Pulmonary Arterial Hypertension | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04991181) |
| August 5, 2021 | NCT04991155 | Effect of Food on BIA 5-1058 | Bial - Portela C S.A. | Phase 1 | Completed | Pulmonary Arterial Hypertension | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04991155) |
| August 4, 2021 | NCT04990284 | eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs. | Bial - Portela C S.A. | Phase 4 | Completed | Parkinson Disease | 106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04990284) |
| August 3, 2021 | NCT04986995 | OpicApone Sleep dISorder | Bial - Portela C S.A. | Phase 4 | Completed | Parkinson Disease | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04986995) |
| August 3, 2021 | NCT04986982 | OpiCapone Effect on Motor Fluctuations and pAiN | Bial - Portela C S.A. | Phase 4 | Completed | Parkinson Disease | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04986982) |
| July 27, 2021 | NCT04978597 | Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study) | Bial - Portela C S.A. | Phase 3 | Completed | Parkinson | 410 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04978597) |
| December 19, 2020 | NCT04675944 | Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil | Bial - Portela C S.A. | Phase 1 | Completed | Pulmonary Arterial Hypertension | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04675944) |
| March 20, 2020 | NCT04316143 | Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat) | Bial - Portela C S.A. | Phase 2 | Completed | Pulmonary Arterial Hypertension | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04316143) |
| February 11, 2020 | NCT04265027 | Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC) | Bial - Portela C S.A. | Phase 1 | Completed | Parkinson Disease | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04265027) |
| August 28, 2019 | NCT04069130 | Absorption, Distribution, Metabolism and Excretion of \[14C\] Labelled BIA 5-1058 | Bial - Portela C S.A. | Phase 1 | Completed | Cardiovascular Diseases | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04069130) |
| May 22, 2019 | NCT03959540 | Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease | Bial - Portela C S.A. | Observational | Completed | Parkinson Disease | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03959540) |
| January 29, 2019 | NCT03820037 | Relative Bioavailability and Bioequivalence of Opicapone | Bial - Portela C S.A. | Phase 1 | Completed | Parkinson Disease | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03820037) |
| October 17, 2018 | NCT03708146 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058 | Bial - Portela C S.A. | Phase 1 | Completed | Cardiovascular Disease+Pulmonary Disease, Pulmonary Arterial Hypertension | 157 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03708146) |
| April 5, 2018 | NCT03489005 | Effect of BIA 5 1058 on Cardiac Repolarization | Bial - Portela C S.A. | Phase 1 | Completed | Cardiovascular Disease, Pulmonary Arterial Hypertension, Heart Failure | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03489005) |
| April 18, 2017 | NCT03119194 | Mass Balance Recovery, Metabolite Profile and Metabolite Identification of \[14C\]-BIA 9-1067 | Bial - Portela C S.A. | Phase 1 | Completed | Parkinson Disease | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03119194) |
| April 17, 2017 | NCT03116321 | Bioequivalence of Two Different Sources of Eslicarbazepine Acetate | Bial - Portela C S.A. | Phase 1 | Completed | Epilepsy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03116321) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 97 |
| Phase 2 | 18 |
| Phase 3 | 13 |
| Phase 4 | 4 |
| Observational | 4 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 129 |
| Terminated | 5 |
| Active not recruiting | 1 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Parkinson Disease | 56 |
| Epilepsy | 44 |
| Pulmonary Arterial Hypertension | 12 |
| Hypertension | 7 |
| Epilepsies, Partial | 7 |
| Heart Failure | 3 |
| Cardiovascular Diseases | 3 |
| Neuralgia, Postherpetic | 2 |
| Diabetic Neuropathies | 2 |
| Fibromyalgia | 1 |
| Neuralgia | 1 |
| Migraine Disorders | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Veterans hospitals in the United States](https://specstream.ai/data/businesses/veterans-hospitals/united-states)
- [Burger restaurants in the United States](https://specstream.ai/data/businesses/burger-restaurants/united-states)
- [Farm equipment repair companies in the United States](https://specstream.ai/data/businesses/farm-equipment-repair-companies/united-states)
- [Live and raw food restaurants in the United States](https://specstream.ai/data/businesses/live-and-raw-food-restaurants/united-states)
- [Pulmonology practices in the United States](https://specstream.ai/data/businesses/pulmonology-practices/united-states)
- [Welding companies in the United States](https://specstream.ai/data/businesses/welding-companies/united-states)
